執行董事 李志晨先生 潘陽先生 胡治東先生 楊明輝女士 非執行董事 OneRobotics (Shenzhen) Co., Ltd. 臥 安 機 器 人（ 深 圳 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 董事名單與角色及職能 臥安機器人（深圳）股份有限公司董事（「董事」）會（「董事會」）的成員載列如下： 李輝女士 梁淑慧博士 王勇教授 董事會設有三個委員會。下表提供各董事於該等委員會中擔任的職位。 | | 董事委員會 | | | | --- | --- | --- | --- | | 董事 | 薪酬與 審核委員會 考核委員會 | | 提名委員會 | | 李志晨先生 | | M | C | | 潘陽先生 | | | | | 胡治東先生 | | M | | | 楊明輝女士 | | | | | 李澤湘教授 | | | | | 高秉強教授 | M | | | | 李輝女士 | C | M | | | 梁淑慧博士 | | M | M | | 王勇教授 | M | C | M | – 1 – 附註： C 有關董事委員會的主席 2025年12月29日 – 2 – 李澤湘教授 高秉強教授 獨立非 ...

OneRobotics (Shenzhen) Co., Ltd. 臥 安 機 器 人（ 深 圳 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 董事會提名委員會工作細則 第一章 總則 第一條 為規範臥安機器人（深圳）股份有限公司（以下簡稱「公司」）董事和高級管理 人員的產生，優化董事會組成，完善公司治理結構，根據《中華人民共和國公司法》 （以下簡稱「公司法」）、香港聯合交易所有限公司證券上市規則（以下簡稱「上市規 則」）、臥安機器人（深圳）股份有限公司的公司章程（以下簡稱「公司章程」）及其他有 關規定，特設立提名委員會（「提名委員會」），並制定本工作細則。 第二條 提名委員會是董事會設立的專門工作機構，主要負責對公司董事和高級管 理人員的人選、選擇標準和程序進行選擇並提出建議。 第三條 本工作細則所稱高級管理人員是指董事會聘任的總經理、副總經理、董事 會秘書、財務負責人及公司章程規定的其他高級管理人員。 第八條 提名委員會負責擬定董事、高級管理人員的選擇標準和程序，對董事、高 級管理人員人選及其任職資格進行遴選、審核，並就下列事項向董事會提出建議： （一）聘任或者解聘高級管理人員； 提名 ...

薪酬與考核委員會工作細則 OneRobotics (Shenzhen) Co., Ltd. 臥 安 機 器 人（ 深 圳 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 第一章 總則 第一條 為進一步建立健全臥安機器人（深圳）股份有限公司（以下簡稱「公司」）董事 及高級管理人員的考核和薪酬管理制度，完善公司治理結構，根據《中華人民共和 國公司法》（以下簡稱「公司法」）、香港聯合交易所有限公司證券上市規則（以下簡稱 「上市規則」）、公司的公司章程（以下簡稱「公司章程」）及其他有關規定，特設立董 事會薪酬與考核委員會，並制定本工作細則。 第二條 薪酬與考核委員會是董事會設立的專門工作機構，主要負責制定公司董事 及高級管理人員的考核標準並進行考核；負責制定、審查公司董事及高級管理人員 的薪酬政策與方案。 第三條 本工作細則所稱的高級管理人員是指經董事會聘任的總經理、副總經理、 財務負責人、董事會秘書、公司章程規定的其他高級管理人員及本公司年報內提及 之同一類別人士。 第二章 人員組成 第四條 薪酬與考核委員會由三名委員組成，大部分成員須為獨立非執行董事。 第五條 薪酬與考核委員會設主任委員（召 ...

OneRobotics (Shenzhen) Co., Ltd. 臥 安 機 器 人（ 深 圳 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 審核委員會工作細則 第一章 總則 第一條 為強化臥安機器人（深圳）股份有限公司（「公司」）董事（「董事」）會（「董事 會」）決策功能，做到事前審計、專業審計，確保董事會對經理層的有效監督，完善 公司治理結構，根據中華人民共和國公司法（「公司法」）、香港聯合交易所有限公司 證券上市規則（「上市規則」）、公司的公司章 程（「公司章程」）及其他有關規定，特 設立董事會審核委員會（「審核委員會」），並制定本工作細則。 第二條 審核委員會是董事會設立的專門工作機構，主要負責指導內部審計部門的 工作、公司內外部審計的溝通、監督和核查工作。 第三條 審核委員會對董事會負責，向董事會報告工作。內部審計部門對審核委員 會負責，向審核委員會報告工作。 第二章 人員組成 第四條 審核委員會由至少三名委員組成，其成員需全部是非執行董事。其中至少 要有一名符合上市規則所規定具備適當專業資格或具備適當的會計或相關的財務管 理專長的獨立非執行董事。審核委員會的成員必須以公司的 ...

臥安機器人（深圳）股份有限公司 公司章程 （草案） – 1 – | | | | 4 | 第一章 | 總則 | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 6 | 經營宗旨及範圍 | 第二章 | | | | | | | | | | | | | | | | | | | | | 6 | 第三章 | 股份、註冊資本和股份轉讓 | | | | | | | | | | | | | | | | | | | | | 6 | 第一節 | 股份發行 | | | | | | | | | | | | | | | | | | | | . | . | . | . | . | . | . | . | . | . | . | . | 10 | 第二節 | 股份增減和回購 | | | | | | | | | . | . | . | . | . | ...

Group 1 - The core viewpoint is that the robot industry is experiencing a surge in IPO applications, particularly in Hong Kong, with over 30 companies in the pipeline, indicating both growth potential and urgency for these firms [2] - The rapid submission of IPO applications by multiple robot companies suggests a recognition of the growth expectations for robotic assets, but it also implies that time is running out for these companies [2] - The industry is facing significant profitability challenges, with high R&D costs, reliance on expensive imported components, and a crowded market leading to delayed profitability for many firms [3][4][6] Group 2 - Companies like Woan Robot are under pressure to achieve profitability, with expectations to turn a profit by mid-2025, while their expenses remain high [3] - Stand Robot has reported cumulative losses of 273 million yuan over three years, primarily due to supply chain issues and reliance on foreign suppliers for critical components [4] - The decline in product prices, while expected with increased production, is also negatively impacting profitability across the sector, as seen with companies like Ledong Robot [6] Group 3 - The capital market is showing signs of tightening, with notable exits from investments, such as Baidu's divestment from Micro Yi Zhi Zao before its IPO [7][8] - The industry is witnessing a wave of bankruptcies, indicating a decrease in investor patience and a potential shift towards a "survival of the fittest" scenario [8][9] - The overall profitability issues in the robot industry stem from mismatches between technological maturity, scalability, and commercial returns, although there are positive signs of progress in domestic component localization and commercialization [10]

本文源自：金融界AI电报 港股今日五只新股齐发，美联股份(02671.HK)暗盘涨约30%，五一视界(06651.HK)暗盘涨约45%，迅策 (03317.HK)暗盘跌35%，林清轩(02657.HK)暗盘涨超27%，卧安机器人(06600.HK)暗盘跌近15%。 ...

Core Viewpoint - Six new companies are set to list on the Hong Kong Stock Exchange on December 30, 2025, marking a significant event referred to as 'six gongs ringing together' [2][10]. Group 1: Company Listings - The companies listing include: 1. **InSilico Medicine (03696.HK)**: An AI-driven drug discovery and development company, with a listing price of HKD 24.05 and issuing 9,469,050 shares, raising approximately HKD 2.277 billion. The company has secured cornerstone investments totaling USD 115 million from 15 investors including Eli Lilly, Tencent, and Temasek [3][11]. 2. **Wuyi Vision (06651.HK)**: A digital twin technology company based in Beijing, with a listing price of HKD 30.50 and issuing 2,397,520 shares, raising around HKD 731 million. It is noted for being the first in the digital twin industry to achieve over HKD 250 million in revenue within a year [3][5]. 3. **Wolan Robotics (06600.HK)**: The largest global provider of AI-driven home robotics systems, with a listing price between HKD 63.00 and HKD 81.00, issuing 2,222,230 shares, raising about HKD 1.8 billion. The company has received cornerstone investments of approximately USD 89.98 million [3][14]. 4. **Lin Qingxuan (02657.HK)**: A high-end domestic skincare brand focusing on anti-aging products, with a listing price of HKD 77.77 and issuing 1,396,645 shares, raising around HKD 1.086 billion. It ranks first among high-end domestic skincare brands in China by retail sales [3][15]. 5. **Xun Ce (03317.HK)**: A data infrastructure and analytics company, with a listing price between HKD 48.00 and HKD 55.00, issuing 2,250,000 shares, raising approximately HKD 1.238 billion. It ranks first in the real-time data infrastructure market for asset management in China [3][6]. 6. **Meilian Holdings (02671.HK)**: A provider of prefabricated steel structure construction services, with a listing price between HKD 7.10 and HKD 9.16, issuing 2,460,000 shares, raising around HKD 225 million. It ranks third in the prefabricated steel structure market in China [3][7]. Group 2: Market Insights - The listing of these companies reflects a growing trend in the Hong Kong market, showcasing advancements in technology and innovation across various sectors, including AI, digital twins, and high-end consumer goods [2][10].

Core Viewpoint - The Hong Kong stock market is entering a significant phase for annual IPOs, with six companies launching their offerings and scheduled to list on December 30, reflecting a strong demand for quality enterprises to utilize market opportunities [1][2]. Group 1: Companies and Their Offerings - Six companies, including Insilico Medicine, Wuyishijie, Xunce, Meilian Holdings, Woan Robotics, and Linqingxuan, are set to launch IPOs, covering diverse sectors such as AI pharmaceuticals, digital twins, home robotics, and high-end skincare [1][2]. - Insilico Medicine, known as a pioneer in AI pharmaceuticals, has set its IPO price at HKD 24.05, aiming to raise HKD 2.277 billion, making it the largest among the six [1]. - Wuyishijie, focusing on digital twin and Physical AI technologies, plans to issue 23.975 million shares at HKD 30.5 each, with a potential fundraising of up to HKD 841 million if the over-allotment option is exercised [2]. - Xunce, a real-time data infrastructure service provider, is expected to raise between HKD 1.08 billion and HKD 1.23 billion, with a share price range of HKD 48-55 [2]. - Woan Robotics, backed by industry figure Li Zexiang, is entering the home robotics sector, while Linqingxuan is offering 13.96645 million shares at HKD 77.77 each [2]. Group 2: Market Trends and Analysis - The concentration of tech and new consumer companies in the IPO market indicates a shift in the structure of IPOs, with technology and new consumption becoming the dominant forces [1][3]. - The traditional industrial sector, represented by Meilian Holdings, highlights the financing needs of transforming traditional industries, aligning with the "technology-led, diversified supplement" structure of the Hong Kong IPO market [3]. - The influx of new IPOs may lead to market differentiation, where the quality of cornerstone investors and the ability to deliver on performance will be critical in distinguishing the companies [3]. - The simultaneous issuance of multiple new stocks may create a fund diversion effect, impacting the demand for public offerings and international placements [3].

New IPOs - The largest biotech IPO in Hong Kong for 2025 is initiated by Insilico Medicine (03696), which boasts the fastest global progress in AI drug development [1] - Lin Qingxuan (02657) will conduct its IPO from December 18 to December 23, attracting cornerstone investors like Fidelity [1] - Woan Robotics (06600) is set to launch its IPO during the same period, with an expected listing date of December 30 [1] - Meilian Holdings (02671) and Wuyi Vision (06651) will also hold their IPOs from December 18 to December 23, both expected to list on December 30 [1] - Xun Ce (03317) will follow the same IPO schedule, with a listing anticipated on December 30 [1] - Zhihui Mining (02546) achieved a remarkable 5248.15 times subscription in its public offering, with a listing date of December 19 [1] - China National Airlines (00753) plans to invest in Shenzhen Airlines' equity financing, with Kunhang Investment, a state-owned entity, being shortlisted [1] - Sensetime-W (00020) intends to place 1.75 billion new Class B shares, aiming to raise approximately HKD 3.146 billion [1] - Fosun Pharma (02196) is enhancing its overseas innovative drug strategy by signing a cooperation and option agreement with Clavis Bio [1] - WuXi AppTec (02359) invested around EUR 30 million to acquire a 3.22% stake in a French biopharmaceutical fund [1] - Minhua Holdings (01999) plans to acquire 100% equity in the American soft furniture company Gainline Recline Intermediate Corp [1] Share Buybacks - Tencent Holdings (00700) repurchased 1.055 million shares for HKD 636 million on December 18 [2] - Xiaomi Group-W (01810) spent HKD 151 million to buy back 3.75 million shares on the same day [2] - COSCO Shipping Holdings (01919) repurchased 5.9 million shares for HKD 80.557 million [2] - Country Garden Services (06098) bought back 2.7 million shares for HKD 17.136 million [2] - Jiangsu Ninghu Expressway (00177) saw an increase of 52.862 million shares by Yunsong Capital [2]